Physician profile
Amanda Worme
NPI 1801248307
$3,614.68
in general payments reported to CMS, 2019-2025
23 companies · $824 in 2025
The $824 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $539 · 2020: $115 · 2021: $423 · 2023: $1,073 · 2024: $641 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,353 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,353.38 |
| Education | $184.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $723.86 | 2021-2025 | Rinvoq |
| Amgen INC. | $522.11 | 2023-2025 | Tavneos, Enbrel, Krystexxa |
| Glaxosmithkline, LLC. | $444.09 | 2019-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $239.44 | 2023-2024 | |
| Janssen Biotech, INC. | $221.49 | 2021-2025 | Tremfya |
| Genzyme Corporation | $184.77 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $147.55 | 2023-2024 | Strensiq |
| E.R. Squibb & Sons, L.L.C. | $135.16 | 2019-2025 | Orencia |
| Mallinckrodt Hospital Products INC. | $131.91 | 2025 | Acthar |
| Edwards Lifesciences Corporation | $125.00 | 2019 | |
| Gilead Sciences, INC. | $121.90 | 2019 | |
| Lilly USA, LLC | $100.40 | 2023-2024 | Taltz |
| Sanofi-Aventis U.S. LLC | $99.00 | 2021 | |
| Pfizer INC. | $69.22 | 2023-2025 | |
| Ucb, INC. | $62.88 | 2025 | Bimzelx |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.40 | 2023 | Ofev, Cyltezo |
| Ani Pharmaceuticals, INC. | $49.26 | 2024-2025 | Sovuna, Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals Lp | $47.13 | 2023 | Saphnelo |
| Horizon Therapeutics Plc | $35.74 | 2023 | Krystexxa |
| Genentech USA, INC. | $33.32 | 2023 | Actemra |
| Organon LLC | $29.94 | 2024 | |
| Sobi, INC | $21.85 | 2023 | |
| Aurinia Pharma U.S., INC. | $12.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Worme listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.